DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Wegovy - 1 Khrysta Baig - 1 Patrick Gleason - 1 Novo - 1 aren't - 1 Gleason - 1 David Lassen - 1 Lassen - 1
Top related locs:
Danish
Top related orgs:
Vanderbilt University - 1 Novo Nordisk - 1 Prime Therapeutics - 1 Therapeutics - 1 U.S - 1 Blue - 1 Thomson - 1

Search resuls for: "Khrysta Baig"


2 mentions found


☆ Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show
  + stars: | 2023-07-11 | by ( Chad Terhune | ) www.reuters.com   time to read: +4 min
The annual cost of overall care for patients prior to taking Wegovy or a similar drug was $12,371, on average, according to the analysis. The costs for a similar control group of patients not taking the drugs decreased by 4% over the same period. The analysis by Prime Therapeutics, a pharmacy benefits manager (PBM), reviewed pharmacy and medical claims data for 4,255 people with commercial health plans. For the analysis, Prime Therapeutics excluded patients with type 2 diabetes to focus on obesity treatment. In trials with adults, Novo found that 6.8% of patients taking Wegovy discontinued treatment due to gastrointestinal problems and other adverse events.
Persons: Wegovy, Khrysta Baig, Patrick Gleason, Novo, aren't, Gleason, David Lassen, Lassen, Chad Terhune, Michele Gershberg, Bill Berkrot Organizations: Reuters, Vanderbilt University, Novo Nordisk, Prime Therapeutics, Therapeutics, U.S, Blue, Thomson Locations: Danish
☆ Economists warn of costs if Medicare covers new obesity drugs
  + stars: | 2023-03-11 | by ( Nancy Lapid | ) www.reuters.com   time to read: +3 min
March 11 (Reuters) - The cost of expanding U.S. Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday. Big-selling diabetes drugs have been repurposed as obesity treatments after demonstrating weight loss of more than 20% in clinical trials. While they are far more effective than older drugs, lifetime use might be required to keep lost weight off. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss. The Medicare health program covers more than 60 million Americans, most over age 65.
0 next >>
Total: 2